Literature DB >> 3757473

Clinical importance of polymicrobial bacteremia.

M P Weinstein, L B Reller, J R Murphy.   

Abstract

Ninety-one episodes of polymicrobial bacteremia and fungemia were compared with 407 unimicrobial episodes to assess differences in the microbiological, epidemiological, and clinical features of the two syndromes. Enterobacteriaceae, nongroup A streptococci, anaerobic bacteria, and pseudomonads were disproportionately common in polymicrobial bacteremia. Polymicrobial episodes were significantly more likely to be hospital-acquired, to emanate from bowel or multiple foci, and to occur in patients with nonhematologic malignancies or multiple underlying diseases. Deaths directly related to sepsis were twofold higher in polymicrobial versus unimicrobial bacteremia. Factors associated with increased mortality in polymicrobial sepsis included age greater than 40 yr; absent or diminished febrile response to sepsis; absolute granulocytopenia; inadequate antimicrobial therapy for all microorganisms isolated; and a primary focus of infection in the bowel, the respiratory tract, an abscess, or an occult site. The occurrence and type of polymicrobial bacteremia can suggest a source of sepsis as well as additional diagnostic and therapeutic maneuvers.

Entities:  

Mesh:

Year:  1986        PMID: 3757473     DOI: 10.1016/0732-8893(86)90001-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  16 in total

1.  Impact of nosocomial polymicrobial bloodstream infections on the outcome in critically ill patients.

Authors:  S Sancho; A Artero; R Zaragoza; J J Camarena; R González; J M Nogueira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

2.  Case mortality in polymicrobial bloodstream infections.

Authors:  F E McKenzie
Journal:  J Clin Epidemiol       Date:  2006-05-02       Impact factor: 6.437

3.  Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia.

Authors:  Agnès Lefort; Xavière Panhard; Olivier Clermont; Paul-Louis Woerther; Catherine Branger; France Mentré; Bruno Fantin; Michel Wolff; Erick Denamur
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

Review 4.  A 'culture' shift: Application of molecular techniques for diagnosing polymicrobial infections.

Authors:  Yi Zhang; Anne Hu; Nadya Andini; Samuel Yang
Journal:  Biotechnol Adv       Date:  2019-02-20       Impact factor: 14.227

5.  Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges.

Authors:  S E Beekmann; D J Diekema; K C Chapin; G V Doern
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

6.  Nosocomial bacteremia in a medical-surgical intensive care unit: epidemiologic characteristics and factors influencing mortality in 111 episodes.

Authors:  J Rello; M Ricart; B Mirelis; E Quintana; M Gurgui; A Net; G Prats
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

7.  Clinical comparison of isolator and thiol broth with ESP aerobic and anaerobic bottles for recovery of pathogens from blood.

Authors:  J A Kellogg; D A Bankert; J P Manzella; K S Parsey; S L Scott; S H Cavanaugh
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

8.  Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. CEMIC (French-Belgian Study Club of Infectious Diseases in Cancer).

Authors:  D Coullioud; P Van der Auwera; M Viot; C Lasset
Journal:  Support Care Cancer       Date:  1993-01       Impact factor: 3.603

Review 9.  Clinical implications of positive blood cultures.

Authors:  C S Bryan
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

10.  Association of secondary and polymicrobial nosocomial bloodstream infections with higher mortality.

Authors:  D Pittet; N Li; R P Wenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.